Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

322.75DKK
17 Apr 2019
Change (% chg)

kr.-8.50 (-2.57%)
Prev Close
kr.331.25
Open
kr.328.45
Day's High
kr.328.60
Day's Low
kr.322.40
Volume
3,591,582
Avg. Vol
2,362,429
52-wk High
kr.349.70
52-wk Low
kr.265.15

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.51
Market Cap(Mil.): kr.610,749.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 3.00
Yield (%): 2.44

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 20.21 29.30 32.55
EPS (TTM): 15.40 -- --
ROI: 76.65 14.23 13.83
ROE: 84.84 15.46 15.25

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

12 Apr 2019

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN, April 12 Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

12 Apr 2019

Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for approval in the United States.

20 Mar 2019

UPDATE 1-Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN, March 20 Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for approval in the United States.

20 Mar 2019

Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN, March 20 Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for U.S. approval.

20 Mar 2019

Novo Nordisk's new diabetes drug, outlook lift shares

COPENHAGEN Novo Nordisk reported solid growth for its new diabetes drug on Friday and said it would submit a tablet version, a key growth hope, for U.S. approval in the first quarter, lifting the Danish drugmaker's shares.

01 Feb 2019

Novo Nordisk CEO backs ending drug industry rebate system

COPENHAGEN The chief executive of drugmaker Novo Nordisk on Friday welcomed a proposal calling for an end to the industry practice of offering after-market discounts called rebates to pharmacy benefit managers.

01 Feb 2019

Novo Nordisk CEO backs ending drug industry rebate system

COPENHAGEN, Feb 1 The chief executive of drugmaker Novo Nordisk on Friday welcomed a proposal calling for an end to the industry practice of offering after-market discounts called rebates to pharmacy benefit managers.

01 Feb 2019

Novo Nordisk's new diabetes drug, outlook lift shares

COPENHAGEN Novo Nordisk reported solid growth for its new diabetes drug on Friday and said it would submit a tablet version, a key growth hope, for U.S. approval in the first quarter, lifting the Danish drugmaker's shares.

01 Feb 2019

UPDATE 3-Novo Nordisk's new diabetes drug, outlook lift shares

* Sees 2019 sales growing 2-5 percent (Adds Brexit comment, U.S. background)

01 Feb 2019

Earnings vs. Estimates